A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

被引：0
|
作者：
Bekaii-Saab, T. [1 ]
Starodub, A. [2 ,3 ]
El-Rayes, B. [4 ]
O'Neil, B. [5 ]
Shahda, S. [5 ]
Ciombor, K. [6 ]
Noonan, A. [6 ]
Hanna, W. [7 ]
Sehdev, A. [5 ]
Shaib, W. [4 ]
Mikhail, S. [6 ]
Neki, A. [6 ]
Oh, C. [8 ]
Li, Y. Z. [8 ]
Li, W. [8 ]
Borodyansky, L. [8 ]
Li, C. J. [8 ]
机构：
[1] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
[2] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA
[3] Parkview Hlth, Ft Wayne, IN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] IU Hlth Univ Hosp, Indianapolis, IN USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Univ Tennessee, Med Ctr, Knoxville, TN USA
[8] Boston Biomed Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA - 002
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Shanda, Safi
    Ciombor, Kristen Keon
    Noonan, Anne M.
    Hanna, Wahid Tewfik
    Sehdev, Amikar
    Shaib, Walid Labib
    Mikhail, Sameh
    Neki, Anterpreet S.
    Oh, Cindy
    Li, Youzhi
    Li, Wei
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    Shahda, Safi
    O'Neil, Bert H.
    Noonan, Anne M.
    Shaib, Walid Labib
    Hanna, Wahid Tewfik
    Mikhail, Sameh
    Neki, Anterpreet S.
    Chang, Yue
    Dai, Xiaoshu
    Li, Wei
    Brooks, Emily
    Oh, Cindy
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
  • [4] CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)
    Bekaii-Saab, T.
    Goldstein, D.
    Li, C. P.
    Okusaka, T.
    O'Neil, B.
    Reni, M.
    Tabernero, J.
    Qin, S.
    Van Cutsem, E.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
    Lee, S. J.
    Oh, D-Y.
    Kang, J-H.
    Choi, H. J.
    Lee, M. A.
    Oh, S. Y.
    Kim, S-T.
    Park, Y. S.
    Ryu, B-Y.
    Park, J. O.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Li, Chung-Pin
    Okusaka, Takuji
    O'Neil, Bert H.
    Reni, Michele
    Tabernero, Josep
    Qin, Shukui
    Van Cutsem, Eric
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    O'Neill, B.
    Tabernero, J.
    Li, C.
    Reni, M.
    Jin, B.
    Oh, C.
    Borodyansky, L.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29
12345